Friday, September 9, 2016

Mycota Spray





1. Name Of The Medicinal Product



Mycota Spray


2. Qualitative And Quantitative Composition



Undecylenic Acid 3.90%w/w



Dichlorophen 0.40 %w/w



For full list of excipients, see section 6.1



3. Pharmaceutical Form



Cutaneous spray, solution



A very pale yellow liquid.



4. Clinical Particulars



4.1 Therapeutic Indications



For the treatment and prevention of athletes foot.



4.2 Posology And Method Of Administration



Route of administration: Cutaneous use



There is no difference between the dosage for adults, children or the elderly.



Treatment



Each night and morning wash and thoroughly dry the affected parts and spray on Mycota Spray. Ensure a generous application between the toes and each day wear clean socks or stockings dusted inside with Mycota Powder or sprayed lightly with Mycota Spray. Continue treatment for one week after all evidence of infection has disappeared.



Prevention



A light spray of Mycota Spray or a dusting of Mycota Powder daily inside clean socks or stockings will help prevent athletes foot.



4.3 Contraindications



Hypersensitivity to Undecylenic Acid, dichlorophen or any of the other ingredients.



Mycota Spray is for external use only. Do not allow the spray to enter the eyes, nose or other body orifices.



4.4 Special Warnings And Precautions For Use



Do not apply to broken skin.



Treatment should be discontinued if irritation is severe.



Caution, Mycota Spray is flammable: Do not use near fire or flame.



Pressurised container: protect from sunlight and do not expose to temperatures exceeding 50°C.



Do not pierce or burn the can, even after use.



Do not spray on a naked flame or any incandescent material.



Do not use near, and do not place the container on, polished or painted surfaces.



Keep out of the reach of children.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



None known



4.6 Pregnancy And Lactation



As with all medicinal compounds care should be taken when administering the product to pregnant or lactating women.



4.7 Effects On Ability To Drive And Use Machines



No or negligible influence.



4.8 Undesirable Effects



Hypersensitivity reactions may occur occasionally. Irritation of the skin may rarely occur.



4.9 Overdose



Owing to the nature of this product and its clinical indications it is highly unlikely that overdose can occur.



Treatment



None stated.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Other antifungals for topical use    D01A E



Undecylenic Acid has antifungal properties being applied topically in the prophylaxis and treatment of dermatophytic infections of superficial areas. Dichlorophen is used as a fungicide.



5.2 Pharmacokinetic Properties



Concentrations of Undecylenic Acid greater than 1 % may cause skin irritation if applied to mucous membranes. It is usually applied to the skin in concentrations of 2-10% and its antifungal activity is greatest at acid pH. As Dichlorophen is included for topical application it is considered that pharmacokinetic data is not applicable.



5.3 Preclinical Safety Data



There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Isopropyl Alcohol



Dipropylene Glycol



Perfume compound SN27673



Hydrocarbon propellant 40



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



36 months



6.4 Special Precautions For Storage



Protect from sunlight and do not expose to temperatures exceeding 30°C.



6.5 Nature And Contents Of Container



Internally lacquered, three piece, tin plate aerosol can with standard aerosol valve and high density polyethylene cap. Can contains 100ml of product.



6.6 Special Precautions For Disposal And Other Handling



Not applicable.



7. Marketing Authorisation Holder



Thornton & Ross Limited



Linthwaite



Huddersfield



West Yorkshire



HD7 5QH



United Kingdom



8. Marketing Authorisation Number(S)



PL 00240/0069



9. Date Of First Authorisation/Renewal Of The Authorisation



6th September 2002



10. Date Of Revision Of The Text



10th June 2010



11 DOSIMETRY (IF APPLICABLE)


Not Applicable



12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)


Not Applicable




No comments:

Post a Comment